Pretomanid
- TRADE NAME: PA-824 (TB Alliance)
- INDICATIONS: Part of a combination regimen with bedaquiline and linezolid for the
treatment of adults with pulmonary extensively drug resistant, treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. - CLASS: Antimycobacterial (including antitubercular)
- HALF-LIFE: 17 hours
FDA APPROVAL DATE: 08/14/2019
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Organic anion transporter-3 substrates, Strong or moderate CYP3A4 inducers
There are no studies or available data on pretomanid use in pregnant women to inform any drug-associated risks. Breastfeeding is not recommended during treatment with pretomanid or with combination therapies.
Pretomanid is indicated for use in a limited and specific population of patients.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
